DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Clinical trials for DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT explained in plain language.
Never miss a new study
Get alerted when new DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT trials appear
Sign up with your email to follow new studies for DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New brain cancer drug shows promise in early trial
Disease control TerminatedThis early-phase study tests whether adding a drug called S-Gboxin to standard treatment can help people with glioblastoma, a fast-growing brain cancer. The drug works by cutting off the energy supply to cancer cells. Ten patients with recurrent or progressive disease will receiv…
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Phase: PHASE1 • Sponsor: Petrov, Andrey • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Engineered t cells take on deadly childhood brain cancer
Disease control OngoingThis early-phase trial tests a new treatment for children and young adults with a rare, aggressive brain tumor called H3.3K27M-mutated diffuse midline glioma. The treatment involves taking a patient's own immune cells (T cells), genetically modifying them in the lab to recognize …
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Phase: PHASE1 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC